CTLA4 and neoplasm: Preclinical studies combining miR-200c mimics with dual anti-PD-1/CTLA-4 blockade achieved tumor regression rates exceeding 60% in lung adenocarcinoma models, compared to 25% with dual checkpoint inhibition alone, while also inducing robust immunological memory that protects against tumor rechallenge [130].